PBS updates

Gazyva (Obinutuzumab)

obinutuzumab 1 g/40 mL injection, 40 mL vial · INJECTION · PBS code 11460E

AUTHORITY_REQUIRED

What it costs

AU$4299.24 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2018-10-01.
  • • Repeats: 7.
  • • PBS program: IN.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Follicular lymphoma


Re-induction treatment


Patient must not have previously received PBS-subsidised obinutuzumab; AND

The condition must be CD20 positive; AND

The condition must be refractory to treatment with rituximab for this condition; AND

The condition must be symptomatic; AND

The treatment must be for re-induction treatment purposes only; AND

The treatment must be in combination with bendamustine; AND

The treatment must not exceed 8 doses for re-induction treatment with this drug for this condition.

The condition is considered rituximab-refractory if the patient experiences less than a partial response or progression of disease within 6 months after completion of a prior rituximab-containing regimen.

A patient may only qualify for PBS-subsidised initiation treatment once in a lifetime under:

i) the previously untreated induction treatment restriction; or

ii) the rituximab-refractory re-induction restriction.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.